does adding aripiprazole to another antipsychotic reliably lower prolactin?

“aeripipyzole specifically if you add it to an antipsychotic, it will actually reliably lower prolactin levels.”

a guest, a professor of psychiatry at Harvard Medical School said on Psychopharmacology and Psychiatry Updates, 2026-09-23, at 05:45. hear it in context →

the episode: Antipsychotics, Prolactin, and Sexual Side Effects (at 05:45). we link the show's own page; we do not re-host audio.

first, the part that holds

the core of the claim holds up. in randomized trials, adding aripiprazole to a prolactin-raising antipsychotic lowers prolactin more than placebo does, and a 2022 network meta-analysis rated the evidence for adjunctive aripiprazole as high certainty.

what we found when we went and looked

we read the pooled trial evidence and one double-blind trial. a 2013 meta-analysis of 5 randomized trials (639 patients) found adjunctive aripiprazole beat placebo at bringing prolactin back to normal (risk difference 0.76, 95% ci 0.67 to 0.85), with 79.11% (125/158) normalizing. a 2022 network meta-analysis of 31 studies (1,999 participants) found prolactin fell by roughly 60 to 68 ng/ml at every dose band, rated high certainty, but only in patients whose prolactin started above 50 ng/ml. below that line, no strategy separated from placebo. "reliably lowers" fits the trials, which almost all enrolled people with clearly raised prolactin. it does not mean every patient normalizes.

assertion by assertion

both directions

for the speaker: every pooled analysis we read points the same way. the 2013 meta-analysis found 79.11% normalization on adjunctive aripiprazole, with adverse-event rates no different from placebo at low doses. the 2022 network meta-analysis found drops of about 60 to 68 ng/ml whether the added dose was 5 mg, 10 mg or more, and graded that evidence high certainty. it also found adding aripiprazole did better than switching strategies in most raised-prolactin subgroups. the double-blind trial in premenopausal women (16 weeks, 46 randomized) found prolactin fell more on aripiprazole than placebo (-26.3 ng/ml, p = .04). galactorrhea improved in 77% vs 33%, and sexual-function scores improved in 25% vs 0%. the 2024 umbrella review concluded adding aripiprazole may be the most appropriate approach.

against: "reliably" carries more than the data show for everyone. in the network meta-analysis, patients with prolactin under 50 ng/ml saw no significant benefit from any option, aripiprazole included. the effect is strongest when prolactin is high to begin with. in the women's trial, the effect was smaller and menstrual recovery did not differ significantly from placebo (46% vs 27%, p = .34). the umbrella review rated the meta-analyses low to very low quality on amstar 2. the trials were mostly short, many came from a narrow set of sites, and several were single-blind. "add it to an antipsychotic" also hides a qualifier: the trials tested it on top of prolactin-raising drugs such as risperidone, paliperidone, amisulpride, sulpiride and haloperidol, in people who already had raised prolactin. they say little about adding it to antipsychotics that barely raise prolactin to begin with.

what this cannot say

the trials measure prolactin and short-term symptoms over 8 to 16 weeks. they cannot say how long the effect lasts, whether long-term outcomes such as bone density improve, or how a given person will respond. pooled estimates carry high heterogeneity (i2 89% in the network meta-analysis). trial populations were mostly people with schizophrenia on a short list of background drugs. on our side: two primary pages (the haloperidol double-blind trial on the journal site, and the women's trial on pubmed) would not load in this session. so we cite only the women's-trial conference abstract we did read, and we do not cite the haloperidol trial's numbers. we read abstracts and summaries, not full-text data tables.

sources, each one fetched and read

1. Li X, et al. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS ONE, 2013. PMC3731351 What we read there: "Meta-analysis of the prolactin level normalization indicated adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random) 0.76 (95% confidence interval 0.67 to 0.85); I2 = 43%, P<0.00001)." "Adjunctive aripiprazole was associated with a 79.11% (125/158) prolactin level normalization rate." 5 RCTs, 639 patients; background drugs risperidone, sulpiride, haloperidol, quetiapine. Fetched 2026-10-06 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC3731351/
2. Lu Z, et al. Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis. Translational Psychiatry, 2022;12:267. PMC9256633 What we read there: 31 studies, 1,999 participants. "All options were not significantly better than placebo among patients with prolactin (PRL) less than 50 ng/ml. However, adjunctive aripiprazole (ARI) (5 mg: MD = −64.26, 95% CI = −87.00 to −41.37; 10 mg: MD = −59.81 ...; more than 10 mg: MD = −68.01 ...) ... were associated with significant decrease ... among patients with PRL more than 50 ng/ml with ... high (adjunctive ARI) certainty of evidence." Fetched 2026-10-06 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC9256633/
3. Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses. Frontiers in Psychiatry, 2024. PMC10948402 What we read there: concludes adding aripiprazole may be the most appropriate approach. rates the included meta-analyses low to very low on AMSTAR 2 and notes short study durations, little dose-finding work and few subgroup analyses by antipsychotic. Fetched 2026-10-06 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC10948402/
4. Treating symptomatic hyperprolactinemia in premenopausal women with severe mental illness: results of the DAAMSEL clinical trial (conference abstract M17). Schizophrenia Bulletin, 2017. PMC5475783 What we read there: 46 women randomized to adjunct aripiprazole 5-15 mg/day (n=25) or placebo (n=21) for 16 weeks. "The prolactin level significantly decreased in the aripiprazole group compared to placebo (estimated difference −26.3 ± 12.6, df = 35, P = .04)." galactorrhea improved in 77% (10/13) vs 33% (4/12). menstruation resumed in 46% vs 27%, P = .34. Fetched 2026-10-06 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC5475783/

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam